Targeting APL Fusion Proteins by Peptide Interference

  • A. Melnick
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 313)


A significant barrier to experimental therapeutics is the ability to identify and specifically target oncogenic proteins involved in the molecular pathogenesis of disease. In acute promyelocytic leukemia (APL), aberrant transcription factors and their associated machinery play a central role in mediating the malignant phenotype. The mechanism of action of APL chimeric fusion proteins involves their ability to either self-associate or interact with different partner proteins. Thus, targeting protein-protein interactions could have a significant impact in blocking the activity of APL oncoproteins. As therapeutic targets, the interface between interacting proteins may not always be amenable to highly specific small molecule blockade. In contrast, peptides are well-suited to this purpose and can be reliably delivered when fused to cell-permeable peptide domains. Therapeutic peptides can be designed to directly target APL fusion proteins, their downstream effectors, or other potentially synergistic oncogenic mechanisms of importance in APL blasts. In addition to serving as potential therapeutic agents, such reagents could serve as powerful reagents to dissect the molecular pathogenesis of APL.


Arsenic Trioxide Protein Transduction Domain Therapeutic Peptide SMRT Corepressor Acute Promyelocytic Leukemia Blast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agou F, Courtois G, Chiaravalli J, Baleux F, Coic YM, Traincard F, Israel A, Veron M (2004) Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. J Biol Chem 279:54248–54257PubMedCrossRefGoogle Scholar
  2. Ahmad KF, Engel CK, Prive GG (1998) Crystal structure of the BTB domain from PLZF. Proc Natl Acad Sci U S A 95:12123–12128PubMedCrossRefGoogle Scholar
  3. Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, Mayer S, Takahashi S, Licht JD, Prive GG (2003) Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 12:1551–1564PubMedCrossRefGoogle Scholar
  4. Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M, Szekely L, Helin K, Pelicci PG (1998) The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol 18:1084–1093PubMedGoogle Scholar
  5. Barka T, Gresik EW, van Der Noen H (2000) Transduction of TAT-HA-betagalactosidase fusion protein into salivary gland-derived cells and organ cultures of the developing gland, and into rat submandibular gland in vivo. J Histochem Cytochem 48:1453–1460PubMedGoogle Scholar
  6. Barka T, Gresik ES, Henderson SC (2004) Production of cell lines secreting TAT fusion proteins. J Histochem Cytochem 52:469–477PubMedGoogle Scholar
  7. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N (2002) The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol 22:1150–1157PubMedCrossRefGoogle Scholar
  8. Belting M, Sandgren S, Wittrup A (2005) Nuclear delivery of macromolecules: barriers and carriers. Adv Drug Deliv Rev 57:505–527PubMedCrossRefGoogle Scholar
  9. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G, Pandolfi PP (2004) Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 199:1545–1557PubMedCrossRefGoogle Scholar
  10. Brooks H, Lebleu B, Vives E (2005) Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 57:559–577PubMedCrossRefGoogle Scholar
  11. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H (2005) Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia 19:1153–1160PubMedCrossRefGoogle Scholar
  12. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG Jr (1999) Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 96:4325–4329PubMedCrossRefGoogle Scholar
  13. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K (2003) Antennapedia and HIV transactivator of transcription (TAT) “protein transduction domains” promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278:35109–35114PubMedCrossRefGoogle Scholar
  14. Contegno F, Cioce M, Pelicci PG, Minucci S (2002) Targeting protein inactivation through an oligomerization chain reaction. Proc Natl Acad Sci U S A 99:1865–1869PubMedCrossRefGoogle Scholar
  15. Crawford M, Woodman R, Ko Ferrigno P (2003) Peptide aptamers: tools for biology and drug discovery. Brief Funct Genomic Proteomic 2:72–79PubMedCrossRefGoogle Scholar
  16. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D (2001) The 104–123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 61:1768–1775PubMedGoogle Scholar
  17. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444–10450PubMedGoogle Scholar
  18. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG (2002) Identification of a zinc finger domain in the human NEIL2 (Nei-like-2) protein. Science 295:1079–1082PubMedCrossRefGoogle Scholar
  19. Dong S, Stenoien DL, Qiu J, Mancini MA, Tweardy DJ (2004) Reduced intranuclear mobility of APL fusion proteins accompanies their mislocalization and results in sequestration and decreased mobility of retinoid X receptor alpha. Mol Cell Biol 24:4465–4475PubMedCrossRefGoogle Scholar
  20. Duprez E, Wagner K, Koch H, Tenen DG (2003) C/EBPbeta: a major PML-RARA responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J 22:5806–5816PubMedCrossRefGoogle Scholar
  21. Elliott G, O’Hare P (1997) Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223–233PubMedCrossRefGoogle Scholar
  22. Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller W H Jr, Lo Coco F, Pelicci PG, Nervi C (2005) Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene 24:1820–1830PubMedCrossRefGoogle Scholar
  23. Ferbeyre G (2002) PML a target of translocations in APL is a regulator of cellular senescence. Leukemia 16:1918–1926PubMedCrossRefGoogle Scholar
  24. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14:2015–2027PubMedGoogle Scholar
  25. Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F (2003) Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther 8:284–294PubMedCrossRefGoogle Scholar
  26. Fischer R, Kohler K, Fotin-Mleczek M, Brock R (2004) A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J Biol Chem 279:12625–12635PubMedCrossRefGoogle Scholar
  27. Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram F, Giacca M (2003) Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278:34141–34149PubMedCrossRefGoogle Scholar
  28. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189–1193PubMedCrossRefGoogle Scholar
  29. Fujimoto K, Hosotani R, Miyamoto Y, Doi R, Koshiba T, Otaka A, Fujii N, Beauchamp RD, Imamura M (2000) Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16(INK4A) fusion peptide in pancreatic cancer cells. Cancer Lett 159:151–158PubMedCrossRefGoogle Scholar
  30. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808–815PubMedGoogle Scholar
  31. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y (2001) Argininerich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836–5840PubMedCrossRefGoogle Scholar
  32. Gallagher RE (2002) Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 16:1940–1958PubMedCrossRefGoogle Scholar
  33. Gery S, Park DJ, Vuong PT, Chih DY, Lemp N, Koeffler HP (2004) Retinoic acid regulates C/EBP homologous protein expression (CHOP), which negatively regulates myeloid target genes. Blood 104:3911–3917PubMedCrossRefGoogle Scholar
  34. Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55:1179–1188PubMedCrossRefGoogle Scholar
  35. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG (1998) Cloning and characterization of a novel human histone deacetylase, HDAC8. Nature 391:815–818PubMedCrossRefGoogle Scholar
  36. Hayakawa F, Privalsky ML (2004) Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5:389–401PubMedCrossRefGoogle Scholar
  37. Hosotani R, Miyamoto Y, Fujimoto K, Doi R, Otaka A, Fujii N, Imamura M (2002) Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res 8:1271–1276PubMedGoogle Scholar
  38. Hu X, Lazar MA (1999) The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93–96PubMedCrossRefGoogle Scholar
  39. Jensen K, Shiels C, Freemont PS (2001) PML protein isoforms and the RBCC/TRIM motif. Oncogene 20:7223–7233PubMedCrossRefGoogle Scholar
  40. Joliot A, Prochiantz A (2004) Transduction peptides: from technology to physiology. Nat Cell Biol 6:189–196PubMedCrossRefGoogle Scholar
  41. Kamashev D, Vitoux D, De The H (2004) PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199:1163–1174PubMedCrossRefGoogle Scholar
  42. Kawasaki A, Matsumura I, Kataoka Y, Takigawa E, Nakajima K, Kanakura Y (2003) Opposing effects of PML and PML/RAR alpha on STAT3 activity. Blood 101:3668–3673PubMedCrossRefGoogle Scholar
  43. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, Morishita H, Saito H, Ueda R, Ohno R (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11:1447–1452PubMedCrossRefGoogle Scholar
  44. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2:183–192PubMedCrossRefGoogle Scholar
  45. Letoha T, Gaal S, Somlai C, Venkei Z, Glavinas H, Kusz E, Duda E, Czajlik A, Petak F, Penke B (2005) Investigation of penetratin peptides. Part 2 In vitro uptake of penetratin and two of its derivatives. J Pept Sci 11:805–811PubMedCrossRefGoogle Scholar
  46. Lin RJ, Nagy L, Inoue S, Shao W, Miller W H Jr, Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811–814PubMedCrossRefGoogle Scholar
  47. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J (1995) Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270:14255–14258PubMedCrossRefGoogle Scholar
  48. Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O, Ferbeyre G (2004) Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23:91–99PubMedCrossRefGoogle Scholar
  49. Melnick A (2005) Predicting the effect of transcription therapy in hematologic malignancies. Leukemia 19:1109–1117PubMedCrossRefGoogle Scholar
  50. Melnick A, Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167–3215PubMedGoogle Scholar
  51. Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Prive GG, Licht JD (2000) In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Mol Cell Biol 20:6550–6567PubMedCrossRefGoogle Scholar
  52. Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD (2002) Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol 22:1804–1818PubMedCrossRefGoogle Scholar
  53. Melnick AM, Adelson K, Licht JD (2005) The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol 23:3957–3970PubMedCrossRefGoogle Scholar
  54. Michod D, Yang JY, Chen J, Bonny C, Widmann C (2004) A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. Oncogene 23:8971–8978PubMedCrossRefGoogle Scholar
  55. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG (2000) Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 5:811–820PubMedCrossRefGoogle Scholar
  56. Moog-Lutz C, Peterson EJ, Lutz PG, Eliason S, Cave-Riant F, Singer A, Di Gioia Y, Dmowski S, Kamens J, Cayre YE, Koretzky G (2001) PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cells. J Biol Chem 276:22375–22381PubMedCrossRefGoogle Scholar
  57. Morris MC, Depollier J, Mery J, Heitz F, Divita G (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173–1176PubMedCrossRefGoogle Scholar
  58. Mourez M, Collier RJ (2004) Use of phage display and polyvalency to design inhibitors of protein-protein interactions. Methods Mol Biol 261:213–228PubMedGoogle Scholar
  59. Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG (2006) ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU. 1 expression. Blood 107:3330–3338PubMedCrossRefGoogle Scholar
  60. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF (1998) Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4:1449–1452PubMedCrossRefGoogle Scholar
  61. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B (2004) The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2:170–182PubMedGoogle Scholar
  62. Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, Melzig M, Bienert M (1998) Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior nonendocytically. Biochim Biophys Acta 1414:127–139PubMedCrossRefGoogle Scholar
  63. Olsnes S, Klingenberg O, Wiedlocha A (2003) Transport of exogenous growth factors and cytokines to the cytosol and to the nucleus. Physiol Rev 83:163–182PubMedGoogle Scholar
  64. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207–210PubMedCrossRefGoogle Scholar
  65. Pescarolo MP, Bagnasco L, Malacarne D, Melchiori A, Valente P, Millo E, Bruno S, Basso S, Parodi S (2001) A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. FASEB J 15:31–33PubMedGoogle Scholar
  66. Polo JM, Dell’oso T, Ranuncolo SM, Cerchietti L, Beck D, DaSilva GF, Prive GG, Licht JD, Melnick A (2004) Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10:1329–1335PubMedCrossRefGoogle Scholar
  67. Pooga M, Hallbrink M, Zorko M, Langel U (1998) Cell penetration by transportan. FASEB J 12:67–77PubMedGoogle Scholar
  68. Potocky TB, Menon AK, Gellman SH (2003) Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J Biol Chem 278:50188–50194PubMedCrossRefGoogle Scholar
  69. Prochiantz A, Joliot A (2003) Can transcription factors function as cell-cell signalling molecules? Nat Rev Mol Cell Biol 4:814–819PubMedGoogle Scholar
  70. Puccetti E, Zheng X, Brambilla D, Seshire A, Beissert T, Boehrer S, Nurnberger H, Hoelzer D, Ottmann OG, Nervi C, Ruthardt M (2005) The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha. Cancer Res 65:6080–6088PubMedCrossRefGoogle Scholar
  71. Racanicchi S, Maccherani C, Liberatore C, Billi M, Gelmetti V, Panigada M, Rizzo G, Nervi C, Grignani F (2005) Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J 24:1232–1242PubMedCrossRefGoogle Scholar
  72. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B (2003) Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278:585–590PubMedCrossRefGoogle Scholar
  73. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV (2005) Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280:15300–15306PubMedCrossRefGoogle Scholar
  74. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–1572PubMedCrossRefGoogle Scholar
  75. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101:5328–5335PubMedCrossRefGoogle Scholar
  76. Snowden AW, Zhang L, Urnov F, Dent C, Jouvenot Y, Zhong X, Rebar EJ, Jamieson AC, Zhang HS, Tan S, Case CC, Pabo CO, Wolffe AP, Gregory PD (2003) Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res 63:8968–8976PubMedGoogle Scholar
  77. Snyder EL, Meade BR, Saenz CC, Dowdy SF (2004) Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2:E36PubMedCrossRefGoogle Scholar
  78. Tallman MS (2004) Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 41:27–32PubMedCrossRefGoogle Scholar
  79. Tyagi M, Rusnati M, Presta M, Giacca M (2001) Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276:3254–3261PubMedCrossRefGoogle Scholar
  80. Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010–16017PubMedCrossRefGoogle Scholar
  81. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP (1999) Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 23:62–66PubMedGoogle Scholar
  82. Wadia JS, Dowdy SF (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57:579–596PubMedCrossRefGoogle Scholar
  83. Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310–315PubMedCrossRefGoogle Scholar
  84. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ (2004) Experimental fat embolism induces urine 2,3-dinor-6-ketoprostaglandin F1alpha and 11-dehydrothromboxane B2 excretion in pigs. Science 305:1466–1470PubMedCrossRefGoogle Scholar
  85. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T, Oh-Hara T, Tsuruo T (2003) Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 63:831–837PubMedGoogle Scholar
  86. Yuan J, Kramer A, Eckerdt F, Kaufmann M, Strebhardt K (2002) Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res 62:4186–4190PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • A. Melnick
    • 1
  1. 1.Department of Developmental and Molecular Biology and Medical OncologyAlbert Einstein College of MedicineBronxUSA

Personalised recommendations